Indazolethylamines

AL-34662 is an indazolethylamine derivative drug that is being developed for the treatment of glaucoma. It acts as a selective serotonin 5-HT2 receptor agonist, including of the 5-HT2A, 5-HT2B, and 5-HT2C receptors (affinity () = 14.5, 8.1, and 3.0nM, respectively). The serotonin 5-HT2A receptor is the same target as that of psychedelic drugs like psilocin. Unlike these drugs however, AL-34662 was designed specifically as a peripherally selective drug, which does not cross the blood–brain barrier. This means that AL-34662 can exploit a useful side effect of the hallucinogenic 5-HT2A receptor a

YM-348 is an indazolethylamine derivative drug which acts as a potent and selective 5-HT2C receptor agonist, with an EC50 of 1nM and 15x selectivity over 5-HT2A, although it only has moderate selectivity of 3x over the closely related 5-HT2B receptor. It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.

AL-38022A is a serotonin receptor agonist and psychedelic drug of the indazolethylamine family related to the psychedelic tryptamine 5-MeO-AMT. It is one of a range of similar drugs developed for scientific research and with some possible clinical applications such as in the treatment of glaucoma. The drug acts as a potent and selective agonist for the 5-HT2 family of serotonin receptors, with highest binding affinity for the 5-HT2C subtype and around four times less affinity for 5-HT2A and 5-HT2B. In drug discrimination tests in animals, it fully substituted for the psychedelic drugs 5-MeO-DM